FDA Approves Tivdak - First Tissue Factor (TF)-Targeted Antibody Conjugate Drug (ADC)
Seagen and Genmab A/S jointly announced recently that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for the antibody conjugate drug (ADC) Tivdak (tisotumab vedotin-tftv) for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after chemotherapy. It is the twelfth ADC approved by FDA.
-
Follow
-
0
-
Embed
-
Share
-
Upload
